CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF
The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of novel cannabidiol compounds.
1 . A compound of the formula (I), or a salt thereof,
where X is one of the following:
2 . A pharmaceutical composition comprising the compound of claim 1 and one or more additional ingredients selected from carriers, diluents (e.g. oils), excipients, adjuvants, fillers, buffers, binders, disintegrants, preservatives, antioxidants, lubricants, stabilisers, solubilisers, surfactants, masking agents, colouring agents, flavouring agents, and sweetening agents.
3 . The pharmaceutical composition of claim 2 in a form selected from a liquid, a solution, a suspension, an emulsion, a syrup, an electuary, a mouthwash, a drop, a tablet, a granule, a powder, a lozenge, a pastille, a capsule, a cachet, a pill, an ampoule, a bolus, a suppository, a pessary, a tincture, a gel, a paste, an ointment, a cream, a lotion, an oil, a foam, a spray, and an aerosol.
4 . The compound of claim 1 , or the pharmaceutical composition of claim 2 or claim 3 , for use in a method of treatment.
5 . The compound of claim 1 , or the pharmaceutical composition of claim 2 or claim 3 , for use in the treatment of epilepsy.
6 . The compound of claim 1 , or the pharmaceutical composition of claim 2 or claim 3 , for use in the treatment of generalised seizure.
7 . The compound of claim 1 , or the pharmaceutical composition of claim 2 or claim 3 , for use in the treatment of tonic-clonic seizure.
8 . The compound of claim 1 , or the pharmaceutical composition of claim 2 or claim 3 , for use as a medicament.
9 . The compound of claim 1 , or the pharmaceutical composition of claim 2 or claim 3 , for use as a medicament for treating epilepsy.
10 . The compound of claim 1 , or the pharmaceutical composition of claim 2 or claim 3 , for use as a medicament for treating generalised seizure.
11 . The compound of claim 1 , or the pharmaceutical composition of claim 2 or claim 3 , for use as a medicament for treating tonic-clonic seizure.
12 . A method of treatment comprising administering to a subject in need of treatment a therapeutically effective amount of the compound of claim 1 or the pharmaceutical composition of claim 2 or claim 3 .
13 . A method of preparing a compound of formula (I), the method comprising:
(1a) reacting a compound of formula (II) with a compound of formula (III):
where:
R 1 and R 2 are OH; or R 1 and R 2 together form —OC(Me) 2 C(Me) 2 O—; and
X 1 is selected from:
14 . The method of claim 13 , wherein step (1a) comprises reacting a compound of formula (II) with a compound of formula (III) and a palladium catalyst.
15 . A method of preparing a compound of formula (I), the method comprising:
(2a) reacting a compound of formula (II) with bis(pinacolato)diboron; and
(2b) reacting the product of step (2a) with a compound of formula (IV),
where:
X 2 is selected from:
16 . The method of claim 15 , wherein step (2a) comprises reacting a compound of formula (II) with bis(pinacolato)diboron and a palladium catalyst.
17 . The method of claim 15 or 16 , wherein step (2b) comprises reacting the product of step (2a) with a compound of formula (IV) and a palladium catalyst.
18 . An intermediate for use in the preparation of a compound formula (I), wherein the intermediate is a compound of formula (II):